Fibrinolytic factors and atherothrombotic events: Epidemiological evidence

Annals of Medicine

Volumn 32, Issue SUPPL. 1, 2000, Pages 85-91

  Folsom, A R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cerebrovascular disease; Coronary disease; Fibrinolysis; Plasminogen activator inhibitor; Tissue plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOLYTIC FACTOR; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; FIBRINOLYSIS; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOGENESIS; THROMBOSIS;

EID: 0034508497     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor
2. The plasminogen (fibrinolytic) system
3. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study
4. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
5. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
6. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
7. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction
8. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction
9. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
10. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
11. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study
12. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina
13. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants
14. Fibrinolytic factors, serum lipid and C-reactive protein predicting cardiac events in Japanese patients with coronary atherosclerotic lesions
15. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm
16. Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function
17. Fibrinogen as a risk factor for stroke and myocardial infarction
18. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
19. Fibrinolytic activity and clotting factors in ischaemic heart disease in women
20. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
21. A prospective study of plasminogen activator inhibitor and the risk of future myocardial infarction
22. Prospective study of endogenous tissue plasminogen activator and risk of stroke
23. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
24. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
25. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independ ent primary risk factor
26. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
27. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study
28. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study
29. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
30. A prospective study of fibrinolytic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
31. TAFI
32. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma
33. Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study
34. Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects
35. Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men
36. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI)
37. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
38. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
39. The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
40. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women
41. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
42. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes
43. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease
44. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study